Influenza genome analysis using pyrosequencing method: Current applications for a moving target

Expert Review of Molecular Diagnostics

Volumn 9, Issue 5, 2009, Pages 493-509

  Deyde, Varough M ^a   Gubareva, Larisa V ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

Adamantane; Antiviral; Avian influenza; H5N1; Neuraminidase inhibitor; Oseltamivir; Resistance; Seasonal influenza

Indexed keywords

ADAMANTANE DERIVATIVE; NUCLEOTIDE; OSELTAMIVIR; PYROPHOSPHATE;

DNA SEQUENCE; GENOME ANALYSIS; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; MICROBIOLOGY; MOLECULAR BIOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOGENOMICS; PYROSEQUENCING; REVIEW; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; DIPHOSPHATES; DRUG RESISTANCE, VIRAL; EXPRESSED SEQUENCE TAGS; GENOME, VIRAL; GENOTYPE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; MOLECULAR DIAGNOSTIC TECHNIQUES; ORTHOMYXOVIRIDAE; OSELTAMIVIR; SEQUENCE ANALYSIS, DNA;

EID: 67650410050     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.09.21     Document Type: Review

References (99)

1. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc. Natl Acad. Sci. USA 74(12), 5463-5467 (1977).
2. Ronaghi M, Karamohamed S, Pettersson B, Uhlen M, Nyren P. Real-time DNA sequencing using detection of pyrophosphate release. Anal. Biochem. 242(1), 84-89 (1996). •• First report describing pyrosequencing approach. (Pubitemid 26378519)
3. Ronaghi M, Uhlen M, Nyren P. A sequencing method based on real-time pyrophosphate. Science 281(5375), 363-365 (1998). (Pubitemid 28340773)
4. Agaton C, Unneberg P, Sievertzon M et al. Gene expression analysis by signature pyrosequencing. Gene 289(1-2), 31-39 (2002). (Pubitemid 34564483)
5. Ahmadian A, Gharizadeh B, Gustafsson AC et al. Single-nucleotide polymorphism analysis by pyrosequencing. Anal. Biochem. 280(1), 103-110 (2000).
6. Gustafsson AC, Guo Z, Hu X et al. HPV-related cancer susceptibility and p53 codon 72 polymorphism. Acta Derm. Venereol. 81(2), 125-129 (2001). (Pubitemid 32662154)
7. Monstein H, Nikpour-Badr S, Jonasson J. Rapid molecular identification and subtyping of Helicobacter pylori by pyrosequencing of the 16S rDNA variable V1 and V3 regions. FEMS Microbiol Lett. 199(1), 103-107 (2001). (Pubitemid 32455471)
8. Nygren M, Ronaghi M, Nyren P, Albert J, Lundeberg J. Quantification of HIV-1 using multiple quantitative polymerase chain reaction standards and bioluminometric detection. Anal. Biochem. 288(1), 28-38 (2001). (Pubitemid 32047641)
9. O'Meara D, Wilbe K, Leitner T, Hejdeman B, Albert J, Lundeberg J. Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing. J. Clin. Microbiol. 39(2), 464-473 (2001). (Pubitemid 32150803)
10. Unnerstad H, Ericsson H, Alderborn A, Tham W, Nielsson-Tham ML, Mattsson JG. Pyrosequencing as a method for grouping of Listeria monocytogenes strains on the basis of single-nucleotide polymorphisms in the inlB gene. Appl. Environ. Microbiol. 67(11), 5339-5342 (2001). (Pubitemid 33701311)
11. Deyde VM, Okomo-Adhiambo M, Sheu TG et al. Pyrosequencing as a tool to detect molecular markers of resistance to NAIs in seasonal influenza A viruses. Antiviral Res. 81(1), 16-24 (2009).
12. Duwe S, Schweiger B. A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1. J. Virol. Methods 153(2), 134-141 (2008).
13. Lackenby A, Democratis J, Siqueira MM, Zambon MC. Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies. Antivir. Ther. 13(6), 809-820 (2008). • Describes application of pyrosequencing for detection of molecular markers of resistance to neuraminidase inhibitors (NAIs) in influenza A viruses.
14. Margulies M, Egholm M, Altman WE et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 437 (7057), 376-380 (2005). • Illustrates use of pyrosequencing principal in complete genome sequencing. (Pubitemid 41613494)
15. Deyde VM, Nguyen T, Bright RA et al. Detection of molecular markers of antiviral resistance in influenza A (H5N1) viruses using pyrosequencing method. Antimicrob. Agents Chemother. 53(2), 1039 (2009). • Reports expansion of pyrosequencing use for detection of most commonly reported molecular markers associated with reduced susceptibility to NAIs in highly pathogenic avian A(H5N1) viruses.
16. Ellis JS, Smith JD, Braham S, Lock M, Barlow K, Zambon MC. Design and validation of an H5 TaqMan real-time one-step RT-PCR and confirmatory assays for detection and verification of influenza A H5 infections in humans. J. Clin. Microbiol. 45(5), 1535-1543 (2007). (Pubitemid 46762410)
17. Pourmand N, Diamond L, Garten R et al. Rapid and highly informative diagnostic assay for H5N1 influenza viruses. PLoS ONE 1, e95 (2006). • Describes application of pyrosequencing in diagnostic of avian A (H5N1) virus infections.
18. Waybright N, Petrangelo E, Lowary P, Bogan J, Mulholland N. Detection of human virulence signatures in H5N1. J. Virol. Methods 154(1-2), 200-205 (2008).
19. Kruckeberg KE, Thibodeau SN. Pyrosequencing technology as a method for the diagnosis of multiple endocrine neoplasia type 2. Clin Chem. 50(3), 522-529 (2004). (Pubitemid 38297301)
20. Gharizadeh B, Nordstrom T, Ahmadian A, Ronaghi M, Nyren P. Long-read pyrosequencing using pure 2′-deoxyadenosine-5′-O′-(1- thiotriphosphate) Sp-isomer. Anal. Biochem. 301(1), 82-90 (2002). (Pubitemid 34113681)
21. Ahmadian A, Ehn M, Hober S. Pyrosequencing: history, biochemistry and future. Clin. Chim. Acta 363(1-2), 83-94 (2006).
22. Chapman KL, Mortier GR, Chapman K, Loughlin J, Grant ME, Briggs MD. Mutations in the region encoding the von Willebrand factor A domain of matrilin-3 are associated with multiple epiphyseal dysplasia. Nat. Genet. 28(4), 393-396 (2001). (Pubitemid 32702433)
23. Magnusson V, Johanneson B, Lima G, Odeberg J, Arcon-Segovia D, Arcon- Riquelme ME. Both risk alleles for FcgRIIA and FcgRIIIA are susceptibility factors for SLE: a unifying hypothesis. Genes Immun. 5(2), 130-137 (2004). (Pubitemid 38967642)
24. Magnusson V, Zunec R, Odeberg J et al. Polymorphisms of the Fc g receptor type IIB gene are not associated with systemic lupus erythematosus in the Swedish population. Arthritis Rheum. 50(4), 1348-1350 (2004). (Pubitemid 38480847)
25. Ronaghi M, Elahi E. Discovery of single nucleotide polymorphisms and mutations by pyrosequencing. Comp. Funct. Genomics 3(1), 51-56 (2002). (Pubitemid 34187811)
26. Gruber JD, Colligan PB, Wolford JK. Estimation of single nucleotide polymorphism allele frequency in DNA pools by using Pyrosequencing. Hum. Genet. 110(5), 395-401 (2002). (Pubitemid 36074985)
27. Rajeevan MS, Swan DC, Duncan K, Lee DR, Limor, JR, Unger ER. Quantitation of site-specific HPV 16 DNA methylation by pyrosequencing. J. Virol. Methods 138(1-2), 170-176 (2006). (Pubitemid 44633461)
28. Uhlmann K, Brinckmann A, Toliat MR, Ritter H, Nurnberg P. Evaluation of a potential epigenetic biomarker by quantitative methyl-single nucleotide polymorphism analysis. Electrophoresis 23(24), 4072-4079 (2002). (Pubitemid 36131460)
29. McCabe KM, Khan G, Zhang YH, Mason EO, McCabe ER. Amplification of bacterial DNA using highly conserved sequences: automated analysis and potential for molecular triage of sepsis. Pediatrics 95(2), 165-169 (1995).
30. Gharizadeh B, Ohlin A, Molling P et al. Multiple group-specific sequencing primers for reliable and rapid DNA sequencing. Mol. Cell. Probes 17(4), 203-210 (2003). (Pubitemid 36999818)
31. Jonasson J, Olofsson M, Monstein HJ. Classification, identification and subtyping of bacteria based on pyrosequencing and signature matching of 16S rDNA fragments. APMIS 110(3), 263-272 (2002). (Pubitemid 34454607)
32. Gharizadeh B, Ghaderi M, Donnelly D, Amini B, Wallin KL, Nyren P. Multipleprimer DNA sequencing method. Electrophoresis 24(7-8), 1145-1151 (2003).
33. Gharizadeh B, Kalantari M, Garcia CA, Johansson B, Nyren P. Typing of human papillomavirus by pyrosequencing. Lab. Invest. 81(5), 673-679 (2001).
34. Elahi E, Pourmand N, Chaung R et al. Determination of hepatitis C virus genotype by Pyrosequencing. J. Virol. Methods 109(2), 171-176 (2003). (Pubitemid 36507105)
35. Towner JS, Sealy TK, Khristova ML et al. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog. 4(11), e1000212 (2008).
36. Yamao T, Eshita Y, Kihara Y et al. Novel virus discovery in field-collected mosquito larvae using an improved system for rapid determination of viral RNA sequences (RDV ver4.0). Arch. Virol. 154 (1), 153-158 (2009).
37. Roszera G, Abbate I, Bruselles A et al. Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations. Retrovirology 6(1), 15 (2009).
38. Simen B, Simons S, Hullsiek K et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J. Infect. Dis. 199(5), 693-701 (2009).
39. Solmone M, Vincenti D, Prosperi MC, Bruselles A, Ippolito G, Capobianchi MR. Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drugresistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J. Virol. 83(4), 1718-1726 (2009).
40. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial analysis of gene expression. Science 270(5235), 484-487 (1995).
41. Nordstrom T, Gharizadeh B, Pourmand N, Nyren P, Ronaghi M. Method enabling fast partial sequencing of cDNA clones. Anal. Biochem. 292(2), 266-271 (2001). (Pubitemid 32458094)
42. Englund JA. Antiviral therapy of influenza. Semin. Pediatr. Infect. Dis. 13(2), 120-128 (2002).
43. Bridges CB, Winquist AG, Fukuda K, Cox NJ, Singleton JA, Strikas RA. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 49(RR-3), 1-38 (2000).
44. Fox JP, Hall CE, Cooney MK, Foy HM. Influenza virus infections in Seattle families, 1975-1979. I. Study design, methods and the occurrence of infections by time and age. Am. J. Epidemiol. 116(2), 212-227 (1982).
45. Glezen WP. Cold-adapted, live attenuated influenza vaccine. Expert Rev. Vaccines 3(2), 131-139 (2004). (Pubitemid 38470523)
46. Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289(2), 179-186 (2003). (Pubitemid 36068705)
47. Bright RA, Medina MJ, Xu X et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366(9492), 1175-1181 (2005). •• Describes the first application of pyrosequencing in the field of influenza. (Pubitemid 41393595)
48. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295(8), 891-894 (2006).
49. Deyde VM, Garten R, Sheu TG, Gubareva LV, Klimov AI. Letter to the Editor: reply to Saito et al. J. Infect. Dis. 197, 632-633 (2008).
50. Deyde VM, Xu X, Bright RA et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J. Infect. Dis. 196(2), 249-257 (2007). (Pubitemid 47047464)
51. Higgins RR, Eshaghi A, Burton L, Mazzulli T, Drews SJ. Differential patterns of amantadine-resistance in influenza A (H3N2) and (H1N1) isolates in Toronto, Canada. J. Clin. Virol. 44(1), 91-93 (2009).
52. Hoper D, Hoffmann B, Beer M. Simple, sensitive, and swift sequencing of complete avian influenza H5N1 genomes. J. Clin. Microbiol. Forthcoming. (2008).
53. Carr MJ, Syare M, Duffy N, Connell J, Hall WW. Rapid molecular detection of the H275Y oseltamivir resistance gene mutation in circulating influenza A (H1N1) viruses. J. Virol. Methods153(2), 257-262 (2008).
54. Bolotin S, Robertson AV, Eshaghi A et al. Development of a novel real-time reverse-transcriptase PCR method for the detection of H275Y positive influenza A H1N1 isolates. J. Virol. Methods (2009) (In Press).
55. Boivin G, Goyette N, Bernatchez H. Prolonged excretion of amantadineresistant influenza a virus quasi species after cessation of antiviral therapy in an immunocompromised patient. Clin. Infect. Dis. 34(5), E23-E25 (2002).
56. Cheung CL, Rayner JM, Smith GJ et al. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J. Infect. Dis. 193(12), 1626-1629 (2006). (Pubitemid 43839465)
57. Hay AJ, Zambon MC, Wolstenholme AJ, Skehel JJ, Smith MH. Molecular basis of resistance of influenza A viruses to amantadine. J. Antimicrob. Chemother. 18(Suppl. B), 19-29 (1986). (Pubitemid 17199048)
58. Klimov AI, Rocha E, Hayden FG, Shult PA, Roumillat LF, Cox NJ. Prolonged shedding of amantadine-resistant influenza A viruses by immunodeficient patients: detection by polymerase chain reactionrestriction analysis. J. Infect. Dis. 172(5), 1352-1355 (1995).
59. Masuda H, Suzuki H, Oshitani H et al. Incidence of amantadine-resistant influenza A viruses in sentinel surveillance sites and nursing homes in Niigata, Japan. Microbiol Immunol. 44(10), 833-839 (2000). (Pubitemid 30800171)
60. Gubareva LV, Webster RG, Hayden FG. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res. 53(1), 47-61 (2002). (Pubitemid 33001554)
61. Mungall BA, Xu X, Klimov A. Assaying susceptibility of avian and other influenza A viruses to zanamivir: comparison of fluorescent and chemiluminescent neuraminidase assays. Avian Dis. 47(3 Suppl.), 1141-1144 (2003). (Pubitemid 37143902)
62. Tisdale M. Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Rev. Med. Virol. 10(1), 45-55 (2000). (Pubitemid 30103133)
63. Wetherall NT, Trivedi T, Zeller J et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J. Clin. Microbiol. 41(2), 742-750 (2003). (Pubitemid 36184190)
64. Ferraris O, Lina B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J. Clin. Virol. 41(1), 13-19 (2008). (Pubitemid 350298978)
65. Hayden FG. Antiviral resistance in influenza viruses - implications for management and pandemic response. N. Engl. J. Med. 354(8), 785-788 (2006). (Pubitemid 43290915)
66. McKimm-Breschkin J, Trivedi T, Hampson A et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob. Agents Chemother. 47(7), 2264-2272 (2003). (Pubitemid 36753582)
67. Monto AS, Kimm-Breschkin JL, Macken C et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 50(7), 2395-2402 (2006). (Pubitemid 43993177)
68. Sheu T, Deyde V, Okomo-Adhiambo M et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide in 2004-2007. Antimicrob. Agents Chemother. 52(9), 3284-3292 (2008).
69. Zambon M, Hayden FG. Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res. 49(3), 147-156 (2001). (Pubitemid 32322468)
70. Abed Y, Bourgault AM, Fenton RJ et al. Characterization of 2 influenza A(H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene. J. Infect. Dis. 86(8), 1074-1080 (2002). (Pubitemid 35177108)
71. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 183(4), 523-531 (2001). (Pubitemid 32147507)
72. Hatakeyama S, Sugaya N, Ito M et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 297(13), 1435-1442 (2007). (Pubitemid 46556469)
73. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J. Infect. Dis. 193(6), 760-764 (2006).
74. Kiso M, Mitamura K, Sakai-Tagawa Y et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364(9436), 759-765 (2004). (Pubitemid 39165094)
75. Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J. Antimicrob. Chemother. 55(Suppl. 1), i5-i21 (2005). (Pubitemid 40331165)
76. Whitley RJ, Hayden FG, Reisinger KS et al. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 20(2), 127-133 (2001). (Pubitemid 32151932)
77. Kramarz P, Monnet D, Nicoll A, Yilmaz C, Ciancio B. Use of oseltamivir in 12 European countries between 2002 and 2007 - lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses. Euro Surveill. 14(5), pii: 19112 (2009).
78. Dharan N, Gubareva L, Meyer J et al. Human infections with oseltamivirresistant influenza A(H1N1) virus in the United States, 2007-2008. JAMA 301 (10), 1034-1041 (2009).
79. Rameix-Welti MA, Enouf V, Cuvelier F, Jeannin P, Van der Werf S. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLOS Pathog. 4(7), e1000103 (2008).
80. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 183(4), 523-531 (2001). (Pubitemid 32147507)
81. Lackenby A, Hungnes O, Dudman SG et al. Emergence of resistance to oseltamivir among influenza A (H1N1) viruses in Europe. Euro Surveill. 13(5), (2008)
82. Barnett JM, Cadman A, Burrell FM et al. In vitro selection and characterization of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir. Virology 265(2), 286-295 (1999). (Pubitemid 30022223)
83. Jackson D, Barclay W, Zurcher T. Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. J. Antimicrob. Chemother. 55(2), 162-169 (2005). (Pubitemid 40331140)
84. de Jong MD, Tran TT, Truong HK et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353(25), 2667-2672 (2005). (Pubitemid 41817715)
85. Le QM, Kiso M, Someya K et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437(7062), 1108 (2005). (Pubitemid 41509341)
86. Collins PJ, Haire LF, Lin YP et al. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453(7199), 1258-1261 (2008). (Pubitemid 351913590)
87. Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, Barr IG. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res. 73(3), 228-231 (2007). (Pubitemid 46273119)
88. McKimm-Breschkin JL, Selleck PW, Usman TB, Johnson MA. Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg. Infect. Dis. 13(9), 1354-1357 (2007). (Pubitemid 47510297)
89. Rameix-Welti MA, Agou F, Buchy P et al. Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir. Antimicrob. Agents Chemother. 50(11), 3809-3815 (2006). (Pubitemid 44684897)
90. Cheng LS, Amaro RE, Xu D, Li WW, Arzberger PW, McCammon JA. Ensemblebased virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase. J Med Chem. 51(13), 3878-3894 (2008). (Pubitemid 351956517)
91. Luo M. Structural biology: antiviral drugs fit for a purpose. Nature 443(7107), 37-38 (2006). (Pubitemid 44344036)
92. Russell RJ, Haire LF, Stevens DJ et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443(7107), 45-49 (2006). (Pubitemid 44344043)
93. Xu X, Zhu X, Dwek RA, Stevens J, Wilson IA. Structural characterization of the 1918 influenza H1N1 neuraminidase. J. Virol. 82(21), 10493-10501 (2008).
94. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 178(5), 1257-1262 (1998). (Pubitemid 28523261)
95. Shu B, Sheu TG, Deyde V et al. Pyrosequencing of real-time RT-PCR amplicons for rapid sequence confirmation and characterization of highly pathogenic avian influenza A(H5N1) viruses. Presented at: Third European Influenza Conference. Vilamoura, Portugal, 14-17 September 2008.
96. Chen GW, Chang SC, Mok CK et al. Genomic signatures of human versus avian influenza A viruses. Emerg. Infect. Dis. 12(9), 1353-1360 (2006).
97. Dharan N, Patton M, Siston A et al. First Reported Outbreak of Oseltamivir- Resistant Influenza A(H1N1) in the United States, Illinois 2008. Emerg. Infect. Dis. (2009) (In Press).
98. Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M, Henfrey RD. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 365(6447), 671-673 (1993).
99. Mashayekhi F, Ronaghi M. Analysis of read length limiting factors in Pyrosequencing chemistry. Anal. Biochem. 363(2), 275-287 (2007). (Pubitemid 46428223)